Elliott builds ‘sizeable’ stake in med tech firm Bio-Rad, WSJ reports

Elliott Investment Management has built a "sizeable" stake in Bio-Rad Laboratories and is expected to push for operational changes to address the stock's underperformance. Bio-Rad shares are down about 18% in 2026 and roughly 70% from their 2021 pandemic-era highs, reflecting fading COVID-testing demand, a weaker Sartorius stake, and softer China demand. The activist involvement could support the shares, but the immediate backdrop remains negative and uncertain.

Analysis

This is less a clean fundamentals story than a governance and capital-allocation reset. A credible activist in a post-pandemic ex-growth name can force a sharper decomposition of the business into stable core vs. stranded assets, and that typically matters more for the multiple than the near-term earnings base. The market is likely underestimating how quickly a credible board/process review can re-rate expectations even before operating performance improves.

The second-order effect is on the strategic investment in Sartorius: if Elliott is active in both holders, Bio-Rad may be pressured to monetize, hedge, or re-sequence that exposure. That could remove an earnings drag, but it also exposes a hidden problem—Bio-Rad has effectively been carrying a non-operating volatility source that may have masked the need for a deeper operational fix. If management resists, the setup becomes a longer-duration stalemate, which tends to keep valuation compressed for quarters rather than weeks.

The core risk is that activism fixes optics faster than economics. Bio-Rad’s end markets likely need a real demand inflection, not just cost cuts, so any rerating without a revenue catalyst may fade once the activist premium is priced in. The upside case is an announced review, asset sale, or capital return plan within 1-3 months; the downside is a proxy fight or partial measures that burn time while China and lab spending remain weak.

Consensus is probably too focused on the headline stake and not enough on what happens if Elliott unlocks a portfolio simplification. If the Sartorius exposure is unwound or hedged, reported earnings volatility could drop materially, which can support a multiple expansion even with flat revenue. That creates a better short-squeeze risk for the stock than a simple mean-reversion setup because positioning is already likely cautious and the catalyst path is event-driven, not macro-driven.

Key Decisions for Investors

• Go long BIO.B on any post-headline consolidation; 3-6 month horizon. The setup favors a 15-25% rerating if Elliott forces a credible strategic review, with limited downside if the activist merely catalyzes better capital discipline.
• Use call spreads on BIO.B rather than outright equity for a 1-3 month catalyst window. Target a defined-risk upside capture into a board/process announcement; downside is capped if the process stalls.
• Avoid shorting into the headline unless the stock spikes materially on no concrete action. Short risk is asymmetric because activism can produce multiple expansion before fundamentals turn, especially in low-conviction, low-growth names.
• If available, hedge any BIO.B long with a basket short of broader lab/tools exposure for 3-6 months. This isolates idiosyncratic activism upside from sector beta and reduces risk if healthcare capex stays weak.
• Watch for any disclosure on Sartorius-related monetization or hedging; that would be the cleaner catalyst than cost cuts. A reduction in non-operating earnings noise would support a higher multiple and is the best risk/reward trigger to add.